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Edited by Veli-Pekka LehtoAbstract Desferoxamine is known to induce apoptosis in cancer
cells, but the mechanisms are still not fully understood. We have
shown that iron(III) is a potent caspase-3 inhibitor, and the inhi-
bition is reversible by the iron chelating agent desferoxamine.
Also, protein disulﬁde isomerase (PDI) is capable of activating
caspase-3 inhibited by iron(III), likely by formation of iron–sul-
fur complex through its active site thiols. Data presented here
suggests that iron(III) could be a potential inhibitor of apoptosis
in vivo, by caspase-3-dependent inhibition with a possibility of
recovery through PDI overexpression.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Apoptosis is a highly regulated process of cell death. Loss of
apoptotic regulation is closely linked to human diseases includ-
ing various forms of cancer, ischemic damage, neurodegenera-
tive diseases and immune disorders [1]. One of the key players
in the process of apoptosis is caspase-3. Caspase-3 belongs to
the family of cysteine-aspartate proteases, involved in the exe-
cution pathway of apoptosis [2,3]. Under normal cellular con-
ditions caspase-3 exists in inactive zymogen form. Upon
oxidative stress, procaspase-3 is autoproteolytically cleaved
resulting in the formation of p20 and p10 domains [4] leading
to assembly of a homodimer of heterodimers which represents
active form of the enzyme [5]. Once activated, caspase-3 is
responsible for proteolytic cleavage of a large number of sub-
strates containing common Asp-Glu-Val-Asp motif such as
PARP [6], U1-70 kDa [7], DNA-PKCS [8], PKC d [9], Hunting-
ton [10] and SREBP-1 [11].
Previous in vitro and in vivo studies have shown that the ac-
tive-site cysteine residue is susceptible to oxidative modiﬁca-
tion which results in caspase-3 inactivation and inhibition of
apoptosis. Nitric oxide (NO) can act as a reversible inhibitor
of caspase-3 activity, by nitrosating its active site cysteine
[12,13]. Reactive oxygen species such as hydrogen peroxide
(H2O2) reversibly inhibit caspase-3 activity [14]. Recent discov-
ery of metal ion-dependent regulation of apoptosis suggested
new mechanisms for caspase-3 inhibition [15,16].*Corresponding author.
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cesses including cell proliferation, electron transfer and detox-
iﬁcation [17]. Intracellular iron traﬃcking occurs through the
cell surface transferrin receptor (TfR) [18,19]. While the
expression of transferrin receptor in non-dividing cells is low,
carcinoma cell lines are associated with overexpression of the
iron receptor [20]. Consequently, increased iron levels have
been observed in various cancer types [21] including HL-60
leukaemic cells, human breast cancer cells and human neuro-
blastoma cells as detected by apoptosis markers amongst
which is an increased caspase-3 activity. However, there has
been no direct evidence of caspase-3 interaction with iron.
Protein disulﬁde isomerase (PDI) is a multifunctional en-
zyme expressed throughout the cell [22,23]. PDI is an abun-
dant protein [35] found in various cell compartments
including ER, cell surface, the cytosol and the nucleus [for re-
view see [36]]. The main function of PDI is isomerization and
rearrangement of disulﬁde bonds [24]. The active site of PDI
contains two vicinal thiols that undergo redox state changes
during catalysis [25]. Recent reports showed that PDI has zinc
[26] and copper [27] binding activity through its active site thi-
ols. PDI active site resembles [2Fe–2S]-ferrodoxin iron biding
domains [28] suggesting that it may bind iron as well.
Here, we present a study on the eﬀects of iron on caspase-3
activity and on the role of PDI in reversing this eﬀect.2. Materials and methods
2.1. Protein expression and puriﬁcation
PDI was expressed and puriﬁed as described in Sliskovic et al. [29].
Protein quantiﬁcation and purity was preformed using the Bradford
assay and gel electrophoresis/Western blotting, respectively.
Active caspase-3 was expressed in E. coli BL21(DE3) with the
expression vector pET-28a as previously described [30]. Puriﬁcation
of caspase-3, protein quantiﬁcation and purity was carried out as de-
scribed in the above paragraph.2.2. Caspase-3 activity
The conditions used for assays of caspase-3 activity are speciﬁed in
ﬁgure legends. Caspase-3 activity was evaluated by measuring proteo-
lytic cleavage of ﬂuorogenic synthetic substrate Ac-DEVD-AMC. As-
say buﬀer contained 100 mM phosphate buﬀer, pH 7.0, unless stated
otherwise. When needed, 100 mM phosphate buﬀer, pH 7.0, was
prepared in MiliQ water (MilliQ synthesis, Millipore) and treated in
Chelex-100 resin (Bio-Rad) to obtain iron-free phosphate buﬀer.
Remaining iron was quantiﬁed as described below. Fluorescence in-
crease due to AMC release was monitored using 360 nm excitation
and 460 nm emission wavelengths. All caspase-3 activity experiments
were performed using Wallac Victor3 1420 Multilabel Counter
(Perkin–Elmer) and Varian Cary Eclipse ﬂuorescence spectrometer.blished by Elsevier B.V. All rights reserved.
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PDI (1 mg) was incubated with 5 · molar excess of Fe2(SO4)3 for 1 h
at room temperature in 100 mM phosphate buﬀer, pH 7.0. Following
incubation, excess iron was removed over Sephadex G-25 with
100 mM phosphate buﬀer, pH 7.0. Final PDI concentration was quan-
tiﬁed using Bradford assay. PDI–Fe was processed immediately for
iron determination.2.4. Iron determination
Quantiﬁcation of complexed iron was done as described by Fish [31],
using Agilent UV–visible spectrophotometer.2.5. Chemical blocking of PDI thiols
PDI active site thiols were chemically modiﬁed using N-ethyl malei-
mide (NEM) and phenylarsine oxide (PAO). Prior to chemical block-
ing, PDI (1 mg) was incubated with 5· molar excess dithiothreitol
(DTT) for 2 h at the room temperature to assure full reduction of
the active site thiols. Excess DTT was removed over Sephadex G-25
using 100 mM phosphate buﬀer, pH 7.0. Reduced PDI was immedi-
ately incubated with 5· molar excess NEM and PAO for 2 h at the
room temperature and chromatographed over Sepadex G-25 column.
Thiol blocking was conﬁrmed with DTNB assay.Fig. 1. Chelating agent dependent activation of caspase-3. Caspase-3
(25 nM) activity was monitored over 15 min in the presence of Ac-
DEVD-AMC (20 lM). Assay buﬀer contained 100 mM phosphate, pH
7.0, EDTA (100 lM), neocuproine (100 lM) or desferoxamine
(100 lM). Final rates were obtained by correcting for the blank rates
without caspase-3 and represented as the percentage of the highest
rate. (*P = 0.01 compared to EDTA, **P = 0.001 as compared to
phosphate buﬀer.)
Fig. 2. Iron dependent inhibition of caspase-3 activation. Caspase-3
(25 nM) activity was assessed by Ac-DEVD-AMC (20 lM) in the
presence of increasing iron concentrations (1–100 lM) in the iron-free
(<50 nM as established by the iron determination as described in
Section 2) phosphate buﬀer. The initial rates were measured over
15 min and corrected for the corresponding controls without caspase-
3. The rates are represented as the percent of caspase-3 without iron.3. Results
Assay conditions for measuring caspase-3 activity in the lit-
erature generally employ chelating agents such as EDTA, as
well as reducing agent DTT in order to maintain the active site
cysteine in its reduced form [32]. We ﬁrst sought to determine
the kinetic parameters of recombinant caspase-3 in the pres-
ence and absence of chelating and reducing agents. EDTA to-
tally abolished the need for employing reducing agents (DTT
or GSH) (Supporting Material, Figure S1 A) indicating that
the inactivation was due to contaminating metal ions.
In the absence of EDTA (Supporting Material, Figure S1 B),
DTT was more successful in activating caspase-3 than GSH.
The apparent KM of caspase-3 was found to be 20 ± 2 lM
in the presence of EDTA (±DTT, GSH) (Figure S1 A) and
15 ± 2 lM in the absence of EDTA (+DTT) (Figure S1 B).
In order to identify the metal ions responsible for caspase-3
inhibition, the activity of the enzyme was measured in the pres-
ence of diﬀerent metal ion chelators. As shown in Fig. 1, be-
sides EDTA, desferoxamine (DFO, 100 lM) was more
successful than neocuproine in restoring caspase-3 (25 nM)
activity. DFO has the highest aﬃnity for Fe(III). Therefore,
the results obtained here suggested that iron is responsible
for inhibiting caspase-3 activity. To further test this hypothesis
the activity of caspase-3 was measured in metal free buﬀer
(Fig. 2). As expected caspase-3 was active in the absence of me-
tal ions. Upon addition of 1–100 lM Fe(III) to 25 nM enzyme,
90 % of the activity was lost. The IC50 estimated for Fe(III)-
mediated inhibition of caspase-3 was 7 ± 2 lM.
Next, we investigated the possibility of PDI to act as a metal
chelator since its active site with the CXXC motif is similar to
[2Fe–2S]-ferrodoxin iron biding domains. To this end caspase-
3 (25 nM) incubated in phosphate buﬀer (100 mM, pH 7.0) re-
sulted in no detectable activity. To this, increasing amounts of
PDI (25 nM to 2.5 lM) were added. The result was a PDI-
dependent increase in caspase-3 activity (Fig. 3A). In similar
experiments caspase-3 activity was monitored in the phosphate
buﬀer (Fig. 2B (r)). Addition of DFO (100 lM) gave rise to an
initial rate v0 of 0.3 lM/min (Fig. 2B (})). In the presence of
PDI (1 lM) the v0 was 2.5-fold larger that observed withDFO alone (Fig. 2B (j)). Caspase-3 activity in the presence
of both PDI DFO gave a v0 that was 14% lower than that
observed with PDI alone (Fig. 3B (h)). These results suggest
that PDI is a better Fe(III) chelator than DFO and raises
the possibility that DFO bound Fe(III) can still bind to the
caspase-3 active site and partially inactivating it.
In a further attempt to demonstrate that the PDI-mediated
activation of caspase-3 was related to Fe(III), PDI (1 lM)
and caspase-3 (25 nM) were added to metal ion free buﬀer
and the initial rates of DEVD-AMC cleavage was monitored
Fig. 3. PDI dependent caspase-3 activation. (A) Initial rates of
caspase-3 activation were monitored in the presence of increasing
PDI concentrations (25–2500 nM), using Ac-DEVD-AMC (20 lM,
over 15 min (inset). Final rates due to presence of PDI were obtained
by subtracting the blank which contained PDI only. (B) The role of
PDI (1 lM) dependent caspase-3 (25 nM) activation was measured in
the presence (white symbols) and absence (black symbols) of DFO
(100 lM), using Ac-DEVD-AMC (20 lM) as the substrate. Traces
shown are representative of caspase-3 activity in the phosphate buﬀer
without (r) and with PDI (j), and DFO containing buﬀer without (})
and with PDI (). The initial rates of caspase-3 activation in the
phosphate buﬀer are represented by black bars, and in the presence of
DFO by white bars (inset). (*P = 0.001). (C) Caspase-3 (25 nM)
activity was monitored by Ac-DEVD-AMC (20 lM) in the presence of
PDI (1 lM), and increasing iron concentrations (1–100 lM). The
initial rates of caspase-3 activity were monitored over 15 min, and
subtracted for the control which did not contain caspase-3.
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PDI-activated caspase-3 activity decreased by 80% in an
[Fe3+]-dependent manner with an apparent IC50 of 3 ± 1 lM.
Next we asked if iron-dependent caspase-3 inhibition was a
reversible process. Initial rate of DEVD-AMC cleavage due to
freshly prepared caspase-3 (25 nM) was inhibited by the addi-
tion of iron (50 lM) (Fig. 4A) and the activity was successfully
restored by the addition of DFO (100 lM). Similarly, caspase-
3 inhibited by the addition of iron could be reactivated by the
addition of either DTT (1 mM) (Fig. 4B, black trace) or PDI
(2 lM) (Fig. 4B, grey trace). These results prompted us to
investigate whether active site thiols are essential for PDI-med-
iated caspase-3 activation. Caspase-3 activation was monitored
in the presence of native PDI and PDI whose active site thiols
were blocked with NEM. Results obtained demonstrate that
modiﬁcation of PDI active site by NEM prevents caspase-3
activation (Fig. 5). In light of these results, the ability of native
PDI to bind iron was tested. PDI pretreated with iron was
found to bind 2 moles of iron per mole of active site thiols
(Fig. 6).Fig. 4. Reversible activation of iron-inhibited caspase-3. (A) Initial
caspase-3 (25 nM) activity in the iron-free phosphate buﬀer, pH 7.0,
was inhibited by addition of iron (50 lM), and followed by reactiva-
tion with DFO (100 lM) (grey trace). Blank (black trace) did not
contain any caspase-3 (n = 3). (B) Caspase-3 (25 nM) activity was
inhibited by addition of iron (50 lM) (a), followed by reactivation with
DTT (1 mM) (black trace, b) and PDI (2 lM) (grey trace, c), (n = 3).
Fig. 5. The role of PDI active site thiols in C3 activation. Caspase-3
(25 nM) activity was monitored in the absence and presence of PDI
and NEM-blocked PDI (1 lM) over 15 min, using Ac-DEVD-AMC
(20 lM). NEM-blocked PDI was prepared as outlined in Section 2.
(P < 0.1).
Fig. 6. PDI-bound iron estimation. Iron estimation was performed for
the PDI samples without iron (PDI control) and with iron incubation
(PDI-Fe). Assay was carried out as described in Section 2.
Fig. 7. Proposed mechanism of caspase-3 regulation in cancer cells.
Cancer cells are associated with overexpression of TfR resulting in
increased levels of intracellular [Fe3+] which could lead to caspase-3
inhibition and suppression of apoptosis. Overexpression of PDI could
restore caspase-3 activity, enabling apoptosis to proceed.
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We have demonstrated that iron(III) can inhibit caspase-3
activity. Activity is restored in the presence of a speciﬁc
iron(III) chelating agent DFO (Fig. 1) and interestingly, in
the presence of PDI (Fig. 3A–C). In addition, PDI appeared
to be better at chelating iron than DFO in that 100-fold lower
[PDI] was able to yield 2-fold larger activity from fully iron-
inactivated caspase. We believe this diﬀerence arises because
the DFO–Fe(III) complex still can interact with the caspase ac-
tive site and partially block its activity. On the other hand, this
is not possible with the much larger PDI–Fe(III) complex
(Fig. 3 B). PDI dependent caspase-3 activation was attenuated
by the addition of iron (Fig. 3C) with an estimated IC50 of
3 lM. These results provided a direct evidence of caspase-3
inhibition by Fe(III), which supports previous observationsthat iron chelating agents can induce apoptosis in various
cancer cell lines.
To date, NO and H2O2 has been shown to reversibly inacti-
vate caspase-3 [13,14,37]. In this study, we were able to show
that iron(III) can also reversibly regulate caspase-3 activity
most likely by interacting with active site Cys285 since the inac-
tivation is reversible by thiol reductants (Figure S1) as well
with iron chelators. In addition our data does not preclude
iron interacting at allosteric sites elsewhere in the molecule.
A role for iron(III) in inactivating caspase-3 was established
by the eﬀect of the Fe(III) speciﬁc chelator DFO on restoring
caspase-3 activity (Fig. 4A) and by the direct inhibition of cas-
pase and PDI-activated caspase by iron(III) (Figs. 2 and 3C,
respectively). The fact that the inhibition by iron(III) is revers-
ible with DFO (and PDI) (Fig. 4A and B, respectively) sug-
gests that iron does not play a role in altering the oxidation
state of the active site Cys285. In addition to DFO, ubiquitous
enzyme PDI was able to mimic the actions of DFO in restoring
caspase-3 activity at physiologically relevant concentrations.
Our data demonstrates that active site thiols of PDI are essen-
tial for caspase-3 activation (Fig. 5). Previous reports demon-
strated that PDI-like proteins such as glutaredoxin are able to
form iron–sulfur complexes [33]. PDI was able to bind iron at
a 2:1 iron:cysteine thiol ratio suggesting that PDI most likely
binds Fe(III) through its active site thiols, as it was shown to
bind Zn and Cu.
Based on our ﬁndings, we are proposing a physiological role
for both Fe(III) and PDI in the modulation of caspase-3 activ-
ity and in the process regulating apoptosis. Previous studies
showed a correlation between cancer cells and increased iron
levels due to (i) increased expression of TfR [20], (ii) increased
ferritin (iron storage) secretion [21] and (iii) ability of desferox-
amine (DFO) to induce apoptosis in cancer cells [17]. Here, we
show that a potential target of Fe(III) is caspase-3, a central
regulator of apoptosis. Therefore, we propose the mechanism
illustrated in Fig. 7 for the regulation of apoptosis by Fe(III)
and PDI. Cells upon becoming cancerous, upregulate TfR
resulting in larger intracellular levels of Fe(III). The Fe(III)
I. Sliskovic, B. Mutus / FEBS Letters 580 (2006) 2233–2237 2237inactivates caspse-3 thus arresting apoptosis. In cells, that suc-
cessfully upregulate and secrete PDI, blocking of caspase-3
activity by Fe(III) would result in the re-initiation of apoptosis
and cell death. These results suggest that substances that in-
duce PDI overexpression [34] could potentially be employed
as new anti-cancer therapeutics.
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